Evidence map›Paper›PMID 41542065›Full record

ArticleResearch square2026

Evaluation of [

Fariha Karim, Agnes P Biju, Christopher Liang, Camryn J Santos, Maharishi Rajarethenam, Jogeshwar Mukherjee

Abstract readPreprint
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Fariha KarimUniversity of California Irvine.ORCID https://orcid.org/0009-0001-3104-9523
Agnes P BijuUniversity of California Irvine.ORCID https://orcid.org/0009-0007-0267-2299
Christopher LiangUniversity of California Irvine.ORCID https://orcid.org/0000-0001-9081-294X
Camryn J SantosUniversity of California Irvine.
Maharishi RajarethenamUniversity of California Irvine.
Jogeshwar MukherjeeUniversity of California Irvine.ORCID https://orcid.org/0000-0003-1009-877X

Funding

Novel Tau-Targeted Radiohalogenated Agents for Alzheimer's DiseaseR01AG077700 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI Jogeshwar Mukherjee · 2024 to 2026
$2.1M
NIA NIH HHS R01 AG077700
6 · The paper itself

Abstract

Alzheimer's disease (AD) and Down Syndrome (DS) are characterized by the aggregation of tau tangles. As a novel tau PET tracer in AD, [

Indexed as

Alzheimer’s diseaseDown SyndromeHarmineImagingMeningesTau

Identifiers

PMID41542065
PMCPMC12803324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.